^
BIOMARKER:

BRAF V600

i
Other names: BRAF, B-raf proto-oncogene, B-raf proto-oncogene, Serine/threonine kinase, V-Raf murine sarcoma viral oncogene homolog B, Serine/threonine-protein kinase B-Raf, Proto-oncogene B-Raf, BRAF1, RAFB1, B-raf proto-oncogene Serine/threonine-protein kinase, Murine sarcoma viral (V-Raf) oncogene homolog B1, B-raf serine/threonine-protein, 94 KDa B-raf protein, B-RAF1
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
Related biomarkers:
BRAF V600
Melanoma
encorafenib + binimetinib
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
BRAF V600
Melanoma
vemurafenib + cobimetinib
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
BRAF V600
Melanoma
pembrolizumab
Sensitive
:
A1
J Am Acad Dermatol - 3 weeks - (New C3)
BRAF V600
Colorectal Cancer
FORE-8394
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
BRAF V600
Pancreatic Cancer
FORE-8394
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
BRAF V600
Glioma
FORE-8394
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
BRAF V600
Thyroid Gland Anaplastic Carcinoma
FORE-8394
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
BRAF V600
Thyroid Gland Papillary Carcinoma
FORE-8394
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
BRAF V600
Melanoma
vorinostat
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
BRAF V600
Melanoma
atezolizumab + vemurafenib + cobimetinib
Sensitive
:
A1
BRAF V600
Melanoma
dabrafenib
Sensitive
:
A1
BRAF V600
Melanoma
trametinib + dabrafenib
Sensitive
:
A1
BRAF V600
Melanoma
trametinib
Sensitive
:
A1
BRAF V600
Melanoma
vemurafenib
Sensitive
:
A1
BRAF V600
Non Small Cell Lung Cancer
trametinib + dabrafenib
Sensitive
:
A1
BRAF V600
Melanoma
nivolumab
Sensitive
:
A1
BRAF V600
Cutaneous Melanoma
trametinib
Resistant
:
A2
BRAF V600
Cutaneous Melanoma
atezolizumab + vemurafenib + cobimetinib
Sensitive
:
A2
BRAF V600
Cutaneous Melanoma
vemurafenib + cobimetinib
Sensitive
:
A2
BRAF V600
Cutaneous Melanoma
encorafenib + binimetinib
Sensitive
:
A2
BRAF V600
Melanoma
BRAF inhibitor + MEK inhibitor
Sensitive
:
A2
BRAF V600
Cutaneous Melanoma
dabrafenib + SNR1611
Sensitive
:
A2
BRAF V600
Cutaneous Melanoma
nivolumab + ipilimumab
Sensitive
:
A2
BRAF V600
Cutaneous Melanoma
pembrolizumab + dabrafenib
Sensitive
:
A2
BRAF V600
Cutaneous Melanoma
pembrolizumab + trametinib
Sensitive
:
A2
BRAF V600
Rectal Cancer
cetuximab + encorafenib
Sensitive
:
A2
BRAF V600
Rectal Cancer
panitumumab + encorafenib
Sensitive
:
A2
BRAF V600
Melanoma
dabrafenib + PDR001 + SNR1611
Sensitive
:
B
BRAF V600
Melanoma
nivolumab + ipilimumab
Sensitive
:
B
BRAF V600
Melanoma
PD1 inhibitor
Sensitive
:
B
BRAF V600
Thyroid Gland Carcinoma
vemurafenib
Sensitive
:
C1
BRAF V600
Ocular Melanoma
vemurafenib
Sensitive
:
C1
BRAF V600
Ocular Melanoma
trametinib + dabrafenib
Sensitive
:
C1
BRAF V600
Multiple Myeloma
encorafenib + binimetinib
Sensitive
:
C1
BRAF V600
Colorectal Cancer
vemurafenib
Sensitive
:
C1
BRAF V600
Cholangiocarcinoma
vemurafenib
Sensitive
:
C1
BRAF V600
Ganglioglioma
vemurafenib
Sensitive
:
C1
BRAF V600
Ovarian Cancer
vemurafenib
Sensitive
:
C1
BRAF V600
Sarcoma
vemurafenib
Sensitive
:
C1
BRAF V600
Non Small Cell Lung Cancer
vemurafenib
Sensitive
:
C1
BRAF V600
Astrocytoma
vemurafenib
Sensitive
:
C1